In the space digest for October 2, a line flashed by that would be easy to read as a technical footnote: the Transporter-18 manifest, among 130 payloads, listed “two reentry vehicles.” Behind that wording lies something almost never seen in orbit. Both vehicles are W-8 and W-9 capsules from Varda Space Industries, and this is the first time 2 commercial return craft have gone into space on a single rocket. Not 2 satellites, not 2 CubeSats—2 objects that, a few months from now, are meant to come back to Earth through the atmosphere.
Readers are usually drawn to the launch: the roar, the booster landing, the price per kilogram going up. What caught me in this news was the other side—the one that almost never makes headlines. For all 50 years of human spaceflight, coming down from orbit was a state privilege: Soyuz (Soyuz) capsules, shuttles, Dragons carrying cargo from the ISS. Now it is a service with a price list, a license, a range, and a payment schedule. And, most interestingly, it costs more than going up.
Varda Space Industries is a California company from El Segundo, founded in January 2021 by 2 people with biographies that speak for themselves: Will Bruey came from SpaceX, where he worked on electronics, while Delian Asparouhov is a partner at Peter Thiel’s Founders Fund. The idea was simple to the point of audacity: send a small vehicle with a reactor for growing drug crystals into orbit, let weightlessness do its work, then bring the result home. A W-series spacecraft weighs around 300 kilograms, enters the atmosphere at roughly 8 kilometers per second, and lands by parachute—on land, not in the ocean.
The first vehicle flew in 2023, and since then the company has reported 6 successful returns. The capsules flew on different Transporter-family launchers—SpaceX’s regular rideshare missions, where dozens of vehicles share a rocket and hitch a ride to space like passengers in the back of a truck. W-4 went up in June 2025, W-5 in November, W-6 in March 2026. There is a conspicuous gap in this sequence: W-7 appears on the lists, but not in the flight record, while W-8 and W-9 launched together.
W-4 deserves separate mention—the only failure in the series—and here the sources contradict one another. Wikipedia says the vehicle failed to return properly and burned up in the atmosphere on May 22, 2026; the German catalog Gunter’s Space Page puts it more gently—the capsule did not deorbit as planned, and the objects remained in low perigee orbit. Varda itself, on the mission page, reports that on May 10 its operators performed a final maneuver to lower the spacecraft’s orbit and shorten its lifespan, “concluding the mission.” The same event is described as an accident, as an unfinished job, and as a routine conclusion—and the public record offers no way to choose between these versions. A telling detail: even in a story as transparent as returning capsules, the official wording and the observers’ catalog differ by 10 days and by an entire meaning.
The first launch of 2 capsules at once is a statement not about hardware, but about operating mode. One vehicle can be managed by hand, summoning engineers in the middle of the night. Two at the same time require a control room, a schedule, and people who know how to watch 2 screens at once. Wendy Shimata, vice president of autonomous systems, put it bluntly: for manufacturing in space to become a real industry, it has to operate like one—high cadence, low cost per mission, and no human in the loop for every decision. The vehicles are now managed from an expanded mission control center in El Segundo itself.
Coming down costs more than going up, and that is not a paradox but arithmetic. NASA publishes a price list for commercial users of the station: delivering cargo to the ISS costs $20,000 per kilogram, returning it costs $40,000. The logic in the comments accompanying that price list is this: what comes down is not just the cargo itself, but the entire machine that first had to go up—a capsule with heat shielding, parachutes, avionics, and a margin of strength. A 20-kilogram package going down brings a ton of hardware with it, and nobody pays for that separately.
Hence the shortage. Look at the table of cargo spacecraft for the station: Progress (Progress), Cygnus, Europe’s ATV, Japan’s HTV—in the “return payload” column, every one has a dash. They deliver and burn up. Exactly 2 types of vehicle can return cargo: Cargo Dragon 2, which brings about 2.5 tons back from the station, and Europe’s Nyx, now under construction, with a projected 2.5 tons down. That is all. Half a century of orbital logistics—and 1 working freight elevator that travels both ways.
Varda has entered this shortage from another direction. Its capsule is not designed for tons: it is a small vehicle whose point is not mass, but that it is the only commercial option available at a price people can afford. Delivering shoebox-sized experiments to orbit costs a customer $25,000–$100,000 per kilogram, if Astral Materials founder Jessica Frick’s estimate is to be believed. Returning that box is a separate line on the invoice.
And now for the most uncomfortable part of this story. Returning from orbit has already become a market. The product for which that market was created does not yet exist.
Varda’s chief revenue officer, Eric Lasker, said it outright: there is not a single product made in space that is now sitting on Earth and that you or I could go out and buy. Not “there are only a few so far,” not “it’s expensive”—it does not exist. Materials already known to be manufacturable in weightlessness cannot find a buyer: improved optical fiber has no customer suffering from that precise problem, and ultrapure semiconductor crystals cannot beat ordinary Earth-made ones on price. Someone in the industry puts the threshold this way: a product from space has to be orders of magnitude better than its terrestrial counterpart, not 1–2% better.
So the money comes not from pharma, but from the Pentagon. According to an industry publication, around 80% of Varda’s revenue comes from federal contracts, and only 1 fifth from pharmaceuticals. In November 2024, the U.S. Air Force awarded the company $48 million to test military payloads on return capsules. In January 2026, that was joined by the MACH-TB 2.0 program: the Test Resource Management Center and a Navy division selected Stratolaunch and Varda for a task requiring reusable, recoverable hypersonic flight testbeds.
The point is simple. A vehicle entering the atmosphere at Mach 25 creates plasma and heating around itself that cannot be reproduced either on a test stand or in a tunnel. Varda has what the military needs, and it is selling not the capsule but space inside it. W-6 carried a nose heat-shield element from Sandia National Laboratories with temperature sensors, and 2 shoulder elements from NASA Ames made using an alternative technology. W-8 carries Canopy Aerospace fiber-optic sensors measuring temperature, heat flux, and shield-material loss directly during descent. W-9 carries a navigation system gathering data at hypersonic speed. Plus external samples of new materials: Syensqo titanium composites, AFRL programs, and some other government tests.
The picture is more honest than the press releases make it sound: today, Varda is not a pharmaceutical company in space, but a test range that is also learning to make medicines. The company does not hide this. “We’re not just building return systems,” Asparouhov says. “We’re building the largest customer for those systems, which is our entire internal pharmaceutical business.” Technology Review described the arrangement in a single phrase: perhaps the only company where hypersonic engineers and pharmaceutical chemists sit under one roof. Of the 6 vehicles sent up, half worked for the military, half for medicine.
There is a thread in this story that usually gets lost behind the technical details: a Varda capsule lands in Australia not because it is cheaper to get there, but because it was not allowed to land in the United States.
In September 2023, the Air Force denied the company a landing at a range in the Utah desert. The wording of the refusal obtained by Ars Technica reads like a verdict without particulars: “based on an overall assessment of safety, risk, and impact.” At the same time, the FAA denied Varda a commercial reentry license. The issue was not the danger posed by the capsule itself, but the way the system is built: in the United States, there is no range whose primary, or even secondary, mission is to support commercial land returns. Everything done before had taken place either in the ocean or at a military range, where a commercial customer is a guest in someone else’s schedule. The company had to align a range window, an air-traffic window, and its own readiness—and the 3 schedules did not line up. Asparouhov later said it plainly: at the FAA’s current staffing level, it is impossible to work that way.
Australia proved to be the answer. In October 2024, the government issued Southern Launch and Varda the country’s first-ever authorization for the return of a spacecraft under the Space (Launches and Returns) Act 2018—and that was aided by the Technology Safeguards Agreement with the United States, which entered into force in the summer of that year and allowed American companies to launch and return vehicles on Australian soil. The Koonibba range in South Australia is tens of thousands of square kilometers of empty land, with no air traffic to reroute and no military whose priorities come first. Speaking of figures: Wikipedia, the Australian Space Agency, and Varda’s own release cite 41,000 square kilometers, while the operator Southern Launch’s own page says 47,000. A difference of 6,000 square kilometers in descriptions of the same range, and nobody explains it.
This land is not unclaimed. The range operates in partnership with the Koonibba Community Aboriginal Corporation—the local Aboriginal community’s corporation—and that is not a line for a corporate social responsibility report: the community consented to the use of the land, receives jobs and investment, and its representatives take part in capsule search and recovery operations. The world’s first commercial landing at a commercial spaceport took place here in February 2025: W-2 touched down at 1 a.m. local time after 45 days in orbit. In September 2025, at a congress in Sydney, the parties signed an extension—another 20 returns through 2028, building toward an almost monthly cadence.
Strip away the pharmaceutical framing, and the market taking shape is a market for the right to drop hardware in the right place. And it has turned out to be broader than 1 company.
In June 2026, SpaceX conducted a demonstration launch of its Starfall capsule, about which it revealed almost nothing: the broadcast was cut after the booster landing, and the number of vehicles aboard was not disclosed. An FAA environmental assessment shows that it is a cylinder roughly 75 centimeters tall and 3 meters in diameter, weighing more than 2 tons and capable of carrying 1 ton of payload, with a splashdown in the Pacific Ocean. At its IPO presentation, SpaceX showed a bus with 4 slots for such capsules and the caption “manufacturing in orbit.” What exactly is inside, and at what price, remains unknown.
Then comes a dense cluster. Inversion Space is testing Arc, a reusable vehicle for “delivering cargo anywhere on Earth in under an hour”; its Ray demonstrator operated in orbit in January 2025, but did not complete its planned reentry. Outpost is building CarryAll, the size of a shipping container, with up to 33 cubic meters of manufacturing capacity in its third version, and it is selling not a capsule but a module: “no company should have to become a space company just to find out whether its product is better in space.” SpaceWorks is preparing the 25-kilogram RED-25 with a steerable parafoil. Reditus has completed the 200-kilogram ENOS and is aiming for the end of 2026. Dispatch promises a 30-kilogram Free Flyer by mid-2027. In Europe, ATMOS has already flown PHOENIX 1 to orbit, The Exploration Company is building Nyx with ESA support, and Sierra Space is preparing a free flight of Dream Chaser for late 2026. In Japan, ElevationSpace is assembling AOBA; in New Zealand, Outlier Space, with a Rocket Lab team, has raised pre-seed funding and is aiming for 2028.
An industry review from mid-2026 puts it soberly: the number of announced vehicles is not proof of a mature market. Many have completed only ground tests. The gap between flight heritage and a funded proposal remains the main one.
And that gives us the answer to the question posed by the hook. Returning from orbit became a business before anyone knew what to bring back. Today’s customer is the state, paying for a few minutes of genuine hypersonics, and it pays reliably because flying on a capsule is cheaper than building a test stand. Pharmaceuticals are the next chapter, and their economics can neither be confirmed nor disproved yet: medicines from space are not being sold because they do not exist. Mach 25 for money is already a commodity. A medicine made in orbit and bought at a pharmacy is still a promise—and the $1.6 billion invested in it rests on the expectation that the promise will come true.